Vir Biotechnology (NASDAQ:VIR) reported quarterly losses of $(1.56) per share which missed the analyst consensus estimate of $(1.05) by 48.57 percent. The company reported quarterly sales of $2.40 million which missed the analyst consensus estimate of $5.51 million by 56.45 percent. This is a 9.06 percent decrease over sales of $2.64 million the same period last year.
Vir Biotechnology Q3 2024 Adj EPS $(1.56) Misses $(1.05) Estimate, Sales $2.40M Miss $5.51M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated